Open AccessLenalidomide Plus Rituximab Chemotherapy for Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas
Author(s) -
Sara D. Khangura,
Andrea Ryce
Publication year - 2021
Publication title -
canadian journal of health technologies
Language(s) - English
Resource type - Journals
ISSN - 2563-6596
DOI - 10.51731/cjht.2021.203
Subject(s) - rituximab , medicine , follicular lymphoma , adverse effect , chop , lenalidomide , lymphoma , placebo , oncology , refractory (planetary science) , non hodgkin's lymphoma , chemotherapy , pathology , multiple myeloma , alternative medicine , physics , astrobiology
Data from 2 randomized controlled trials indicated a statistically significant benefit in progression-free survival and overall survival for patients with follicular lymphoma who received R2 as compared to patients who received rituximab plus placebo or R-CHOP.
The frequency of all types of adverse events in patients receiving R2 as compared to rituximab plus placebo or R-CHOP was comparable, but patients receiving R2 experienced more severe adverse events.
Two economic analyses concluded that R2 was cost-effective for the treatment of patients with follicular lymphoma as compared to rituximab plus placebo (UK and Dutch contexts).
Evidence identified in this review was mostly limited to that describing patients with follicular lymphoma.
Most evidence identified in this review was generated with support and/or funding from a private industry pharmaceutical manufacturer.